WallStreetZenWallStreetZen

NASDAQ: ARDX
Ardelyx Inc Stock

$7.30-0.11 (-1.48%)
Updated Mar 28, 2024
ARDX Price
$7.30
Fair Value Price
N/A
Market Cap
$1.70B
52 Week Low
$3.16
52 Week High
$10.13
P/E
-24.33x
P/B
10.18x
P/S
10.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$124.46M
Earnings
-$66.07M
Gross Margin
85.7%
Operating Margin
-48.67%
Profit Margin
-53.1%
Debt to Equity
0.78
Operating Cash Flow
-$90M
Beta
1.1
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ARDX Overview

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ARDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ARDX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ARDX is poor value based on its book value relative to its share price (10.18x), compared to the US Biotechnology industry average (6.21x)
P/B vs Industry Valuation
ARDX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ARDX due diligence checks available for Premium users.

Be the first to know about important ARDX news, forecast changes, insider trades & much more!

ARDX News

Valuation

ARDX fair value

Fair Value of ARDX stock based on Discounted Cash Flow (DCF)
Price
$7.30
Fair Value
-$9.64
Undervalued by
175.70%
ARDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ARDX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-24.33x
Industry
14.26x
Market
44.51x

ARDX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
10.18x
Industry
6.21x
ARDX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ARDX's financial health

Profit margin

Revenue
$34.4M
Net Income
-$28.8M
Profit Margin
-83.8%
ARDX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ARDX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$297.6M
Liabilities
$130.8M
Debt to equity
0.78
ARDX's short-term assets ($246.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARDX's short-term assets ($246.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARDX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ARDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$8.7M
Investing
-$29.6M
Financing
$26.0M
ARDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ARDX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ARDX$1.70B-1.48%-24.33x10.18x
EWTX$1.70B+1.56%-11.62x5.33x
AUTL$1.70B+2.24%-5.32x15.22x
PTGX$1.69B+1.58%-20.81x5.01x
RCUS$1.72B+3.68%-4.55x3.71x

Ardelyx Stock FAQ

What is Ardelyx's quote symbol?

(NASDAQ: ARDX) Ardelyx trades on the NASDAQ under the ticker symbol ARDX. Ardelyx stock quotes can also be displayed as NASDAQ: ARDX.

If you're new to stock investing, here's how to buy Ardelyx stock.

What is the 52 week high and low for Ardelyx (NASDAQ: ARDX)?

(NASDAQ: ARDX) Ardelyx's 52-week high was $10.13, and its 52-week low was $3.16. It is currently -27.94% from its 52-week high and 131.01% from its 52-week low.

How much is Ardelyx stock worth today?

(NASDAQ: ARDX) Ardelyx currently has 232,686,008 outstanding shares. With Ardelyx stock trading at $7.30 per share, the total value of Ardelyx stock (market capitalization) is $1.70B.

Ardelyx stock was originally listed at a price of $14.11 in Jun 19, 2014. If you had invested in Ardelyx stock at $14.11, your return over the last 9 years would have been -48.26%, for an annualized return of -7.06% (not including any dividends or dividend reinvestments).

How much is Ardelyx's stock price per share?

(NASDAQ: ARDX) Ardelyx stock price per share is $7.30 today (as of Mar 28, 2024).

What is Ardelyx's Market Cap?

(NASDAQ: ARDX) Ardelyx's market cap is $1.70B, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Ardelyx's market cap is calculated by multiplying ARDX's current stock price of $7.30 by ARDX's total outstanding shares of 232,686,008.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.